Tolerance of didanosine as enteric-coated capsules versus buffered tablets.
Barreiro
Pablo
P
Service of Infectious Diseases. Hospital Carlos III. Madrid, Spain.
Corbatón
Arturo
A
Núñez
Marina
M
González-Lahoz
Juan
J
Soriano
Vincent
V
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016049:Didanosine / Q000008:administration & dosage* / Q000009:adverse effects; D004304:Dosage Forms; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012189:Retrospective Studies
D019380:Anti-HIV Agents; D004304:Dosage Forms; D016049:Didanosine